ARCHER® FUSIONPlex®

Comprehensive target list

	FusionPlex Sarcoma	FusionPlex ALK, RET, ROS1 v2	FusionPlex CTL	FusionPlex Solid Tumor	FusionPlex Oncology Research
Sequencing reads required:	1.5M	1M	1.5M	3M	3M
ABL1					ABL1
ABL2					ABL2
AKT1			AKT1		AKT1
AKT2					AKT2
AKT3				AKT3	AKT3
ALK	ALK	ALK	ALK	ALK	ALK
ARHGAP26				ARHGAP26	ARHGAP26
AXL			AXL	AXL	AXL
BRAF			BRAF	BRAF	BRAF
BRD3				BRD3	BRD3
BRD4				BRD4	BRD4
CALCA			CALCA		
CAMTA1	CAMTA1				
CCNB3	CCNB3				
CCND1			CCND1		
CIC	CIC				
CRLF2					CRLF2
CSF1R					CSF1R
CTNNB1			CTNNB1		
DDR2			DDR2		
EGFR			EGFR	EGFR	EGFR
EPC1	EPC1				
EPOR					EPOR
ERBB2			ERBB2		ERBB2
ERBB4					ERBB4
ERG				ERG	ERG
ESR1				ESR1	ESR1
ESRRA				ESRRA	ESRRA
ETV1				ETV1	ETV1
ETV4				ETV4	ETV4
ETV5				ETV5	ETV5
ETV6				ETV6	ETV6
EWSR1	EWSR1			EWSR1	EWSR1
FGFR1			FGFR1	FGFR1	FGFR1
FGFR2			FGFR2	FGFR2	FGFR2
FGFR3			FGFR3	FGFR3	FGFR3
FGR				FGR	FGR
FOXO1	FOXO1				
FUS	FUS				
GLI1	GLI1				
GNAS			GNAS		
HMGA2	HMGA2				
HRAS			HRAS		
IDH1			IDH1		
IDH2			IDH2		
IL2RB					IL2RB
INSR				INSR	INSR
JAK1					JAK1
JAK2					JAK2
JAK3					JAK3
JAZF1	JAZF1				

ALK RET ROS1 v2

Essential 29-target assay detects gene-fusions and key resistance mutations in ALK, RET, and ROS1

CTL - Thyroid/Lung

Focused 195-target assay identifies gene-fusions and SNVs implicated in thyroid and lung cancers, including MET and EGFR splicing

Solid Tumor

Comprehensive 288-target assay uncovers gene-fusions in 53 genes associated with various carcinomas, including MET and EGFR splicing

Oncology Research

Expansive 393-target assay reveals gene fusions and key resistance mutations in 75 cancer-related genes, including those observed in Ph-like ALL, with MET and EPOR splicing

KIT					KIT
KRAS			KRAS		
KRT20			KRT20		
KRT7			KRT7		
MAML2				MAML2	MAML2
MAP2K1			MAP2K1		
MAST1				MAST1	MAST1
MAST2				MAST2	MAST2
MEAF6	MEAF6				
MET			MET	MET	MET
MKL2	MKL2				
MSMB				MSMB	MSMB
MUSK				MUSK	MUSK
MYB				MYB	MYB
MYC					MYC
NCOA2	NCOA2				
NOTCH1				NOTCH1	NOTCH1
NOTCH2				NOTCH2	NOTCH2
NRAS			NRAS		
NRG1			NRG1	NRG1	NRG1
NTRK1			NTRK1	NTRK1	NTRK1
NTRK2			NTRK2	NTRK2	NTRK2
NTRK3	NTRK3		NTRK3	NTRK3	NTRK3
NUMBL				NUMBL	NUMBL
NUTM1				NUTM1	NUTM1
PDGFB	PDGFB				
PDGFRA				PDGFRA	PDGFRA
PDGFRB				PDGFRB	PDGFRB
PIK3CA			PIK3CA	PIK3CA	PIK3CA
PKN1				PKN1	PKN1
PLAG1	PLAG1				
PPARG			PPARG	PPARG	PPARG
PRKCA				PRKCA	PRKCA
PRKCB				PRKCB	PRKCB
PTH			PTH		
PTK2B					PTK2B
RAF1			RAF1	RAF1	RAF1
RARA					RARA
RELA				RELA	RELA
RET		RET	RET	RET	RET
ROS1	ROS1	ROS1	ROS1	ROS1	ROS1
RSPO2				RSPO2	RSPO2
RSPO3				RSPO3	RSPO3
SLC5A5			SLC5A5		
SS18	SS18				
STAT6	STAT6				
SYK					SYK
TAF15	TAF15				
TCF12	TCF12				
TERT				TERT	TERT
TFE3	TFE3			TFE3	TFE3
TFEB				TFEB	TFEB
TFG	TFG				
THADA			THADA	THADA	THADA
TMPRSS2				TMPRSS2	TMPRSS2
TSLP					TSLP
TTF1			TTF1		
TYK2					TYK2
USP6	USP6				
YWHAE	YWHAE				



Sarcoma

Consolidated 148-target assay exposes known and novel fusions in 26 genes commonly associated with soft tissue cancers

ARCHER®

SureShot™

Fusion Controls

The Archer SureShot ALK, RET, ROS1 Positive Controls consist of 4 FFPE curls containing cell lines with physiologically relevant abundance of ALK, RET and ROS1 fusions, specifically:

- EML4-ALK variant 1
- ROS1-SL34A2
- RET-CCDC6

Each curl contains a defined mixture of 3 different ALK, RET, and ROS1 fusion-positive cell lines along with a wild-type parental strain.

SureShot Positive and Negative controls are suitable for use with all FusionPlex panels containing these genes.

illumina® | ARCHER®

Learn more at archerdx.com/fusionplex